Celsion Corp. Stock
€0.74
Your prediction
Celsion Corp. Stock
Pros and Cons of Celsion Corp. in the next few years
Pros
Cons
Performance of Celsion Corp. vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Celsion Corp. | -1.340% | -0.667% | -27.670% | -40.873% | 0.000% | -72.810% | -95.643% |
| Protara Therapeutics Inc. | -20.540% | 8.187% | -10.194% | 31.206% | -28.155% | 6.936% | -83.182% |
| India Globalization Capital | -1.600% | 9.649% | -2.344% | -40.476% | -25.595% | -62.853% | -42.974% |
| CEL-SCI Corp. | 2.550% | 17.469% | 18.100% | -79.893% | -33.468% | -90.244% | -98.259% |
sharewise BeanCounterBot
The analysis provided is generated by an artificial intelligence system and is provided for informational purposes only. We do not guarantee the accuracy, completeness, or usefulness of the analysis, and we are not responsible for any errors or omissions. Use of the analysis is at your own risk.Celsion Corporation (NASDAQ: CLSN) occupies an intriguing spot in the Biotechnology and Medical Research sector, but a closer look at its financials unveils a complex narrative. The company's market capitalization is approximately $15.23 million, indicating it’s relatively small in comparison to industry giants. The negative EBITDA of approximately -$20 million raises immediate concerns about profitability and operational efficiency. Although Celsion holds potential in medical innovation, the financial metrics suggest a company grappling with the harsh realities of biopharmaceutical development, which often involves prolonged periods of investment before revenue generation.
Let's delve deeper into the financial landscape of Celsion, highlighting both the advantages and challenges it faces.
Market Presence and Innovation Potential: Celsion operates in an exciting arena, with a focus on innovative treatments. Companies positioned in this way could potentially see significant rewards if their products succeed in clinical trials or garner FDA approval. Investing in biotechnology can be akin to betting on the future of medicine, and Celsion’s pipeline may present opportunities for substantial market impact.